Open access
Sep 2026
A PRK-armed oncolytic adenovirus drives calreticulin exposure for dendritic cell licensing to prime antitumor CD8⁺ T cells and synergizes with anti-PD-1 or CAR-T therapy in colorectal cancer.
BACKGROUND The therapeutic potential of oncolytic adenoviruses (ADVs) in colorectal cancer is constrained by a counterproductive host response: virus-triggered hyperactivation of the pro-survival AKT pathway, which fosters an immunosuppressive tumor microenvironment. METHODS We engineered a novel oncolytic adenovirus...
Yan Liu, Bei-Bei Ran, Ling-Kai Kong et al.
· Journal of gastroenterology · 0 citations